RELVAR ELLIPTA

USDailyMed:Fluticasone and vilanterol R03AK10(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) D10501 Fluticasone furoate/vilanterol, sold under the brand namesBreo ElliptaandRelvar Elliptaamong others, is acombination medicationfor the treatment ofchronic obstructive pulmonary disease(COPD) andasthma.It containsfluticasone furoate, an inhaledcorticosteroid, andvilanterol, an ultra-long-acting β2agonist(ultra-LABA). In 2013, the drug was approved for use in the United States by theFood and Drug Administration(FDA) for long-term maintenance treatment of airflow obstruction in people with COPD, including chronicbronchitisandemphysema,and theEuropean Medicines Agencyapproved it as asecond-line therapyfor the treatment of COPD and asthma.There were, however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma. In 2017, the FDA states that they were not justified. It is on theWorld Health Organization's List of Essential Medicines.In 2023, it was the 139th most commonly prescribed medication in the United States, with more than 4million prescriptions.